China Compliance Update: Commercial Bribery Risks Remain Very Real in China
By EsqSocial Corporation 13/02/14
The enactment of new legislation, as well as new and continuing investigations, demonstrates that Chinese regulators have not slowed down their efforts to ferret out corruption in the pharmaceutical sector and related industries....
By: McDermott Will & Emery